Abstract
Thrombospondin-1 is the first and most studied naturally occurring protein inhibitor of angiogenesis. Its characteristic multi-domain structure determines thrombospondin-1 divergent functions, which include but are not limited to the regulation of angiogenesis. Below we overview the structural determinants and receptors expressed on the endothelial and other cell types, that are at the root of thrombospondin-1 striking ability to block neovascularization. We specifically emphasize thrombospondin-1 direct apoptotic action on the remodeling vascular endothelium and summarize current knowledge of its pro-apoptotic signaling and transcriptional networks. Further, we provide comprehensive survey of the thrombospondin-based anti-angiogenic strategies with special focus on the combination treatments. We convincingly illustrate how precise knowledge of the pro-apoptotic events and intermediates elicited by thrombospondin in the vascular endothelial cells facilitates the design of the most effective treatment combinations, where the efficacy of thrombospondin- derived compounds is maximized by the partner drug(s) (“complementation” strategies) and provide examples of such fine-tuning of the thrombospondin-based anti-angiogenic treatments.
Keywords: Thrombospondin, angiogenesis, apoptosis, complementation treatment
Current Drug Targets
Title: Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Volume: 9 Issue: 10
Author(s): Y. Mirochnik, A. Kwiatek and O. V. Volpert
Affiliation:
Keywords: Thrombospondin, angiogenesis, apoptosis, complementation treatment
Abstract: Thrombospondin-1 is the first and most studied naturally occurring protein inhibitor of angiogenesis. Its characteristic multi-domain structure determines thrombospondin-1 divergent functions, which include but are not limited to the regulation of angiogenesis. Below we overview the structural determinants and receptors expressed on the endothelial and other cell types, that are at the root of thrombospondin-1 striking ability to block neovascularization. We specifically emphasize thrombospondin-1 direct apoptotic action on the remodeling vascular endothelium and summarize current knowledge of its pro-apoptotic signaling and transcriptional networks. Further, we provide comprehensive survey of the thrombospondin-based anti-angiogenic strategies with special focus on the combination treatments. We convincingly illustrate how precise knowledge of the pro-apoptotic events and intermediates elicited by thrombospondin in the vascular endothelial cells facilitates the design of the most effective treatment combinations, where the efficacy of thrombospondin- derived compounds is maximized by the partner drug(s) (“complementation” strategies) and provide examples of such fine-tuning of the thrombospondin-based anti-angiogenic treatments.
Export Options
About this article
Cite this article as:
Mirochnik Y., Kwiatek A. and Volpert V. O., Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments, Current Drug Targets 2008; 9 (10) . https://dx.doi.org/10.2174/138945008785909347
DOI https://dx.doi.org/10.2174/138945008785909347 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Synergistic Effect of Immunotherapy and Chemotherapy in Cancers: Perspective in High Grade Glioma Treatment
Letters in Drug Design & Discovery Nanotools for the Delivery of Antimicrobial Peptides
Current Drug Targets PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research C-Myc Signaling Pathway in Treatment and Prevention of Brain Tumors
Current Cancer Drug Targets Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
Anti-Cancer Agents in Medicinal Chemistry Oxidative Stress and NAD+ in Ischemic Brain Injury: Current Advances and Future Perspectives
Current Medicinal Chemistry The Application of Stimuli-responsive Nanocarriers for Targeted Drug Delivery
Current Topics in Medicinal Chemistry A Connecting Switch Among Aging, Diabetes and Tumor: Avenue Leading to Cancer Therapeutics
Current Cancer Therapy Reviews Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Nucleic Acid-Based Therapeutics for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry